Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Open-Label Study of Atezolizumab With Bevacizumab and/or Other Treatments in Solid Tumors
jRCT2080223750Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial in Nonhematologic neoplasms and hepatocellular carcinoma (HCC) comparing Atezolizumab monotherapy with Atezolizumab + bevacizumab (2 arms). Primary endpoint: Safety and tolerability of atezolizumab in combination with bevacizumab and/or other treatments. Started Dec 2017; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080223750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223750.